ZA200301013B - Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors. - Google Patents
Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors. Download PDFInfo
- Publication number
- ZA200301013B ZA200301013B ZA200301013A ZA200301013A ZA200301013B ZA 200301013 B ZA200301013 B ZA 200301013B ZA 200301013 A ZA200301013 A ZA 200301013A ZA 200301013 A ZA200301013 A ZA 200301013A ZA 200301013 B ZA200301013 B ZA 200301013B
- Authority
- ZA
- South Africa
- Prior art keywords
- carbamoyl
- thieno
- pyrrole
- dichloro
- amino
- Prior art date
Links
- -1 Bicyclic pyrrolyl amides Chemical class 0.000 title claims description 287
- 239000003112 inhibitor Substances 0.000 title description 3
- 102000009097 Phosphorylases Human genes 0.000 title description 2
- 108010073135 Phosphorylases Proteins 0.000 title description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 128
- 125000000217 alkyl group Chemical group 0.000 claims description 79
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 62
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 52
- 125000000623 heterocyclic group Chemical group 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 38
- 229910052757 nitrogen Inorganic materials 0.000 claims description 38
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 229910052799 carbon Inorganic materials 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 150000002431 hydrogen Chemical class 0.000 claims description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 23
- 150000002148 esters Chemical class 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 102000007390 Glycogen Phosphorylase Human genes 0.000 claims description 12
- 108010046163 Glycogen Phosphorylase Proteins 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 9
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 8
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 7
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000005002 aryl methyl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 5
- 125000001589 carboacyl group Chemical group 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 4
- 239000005864 Sulphur Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 239000000126 substance Substances 0.000 claims 8
- 125000004130 indan-2-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])(*)C2([H])[H] 0.000 claims 2
- UYGMKKAFEMEBKS-UHFFFAOYSA-N 2,3-dichloro-n-(1-hydroxy-2,3-dihydro-1h-inden-2-yl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(O)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 UYGMKKAFEMEBKS-UHFFFAOYSA-N 0.000 claims 1
- FSFFDXIWVZJNNU-UHFFFAOYSA-N 2,3-dichloro-n-(1-hydroxy-3-phenylpropan-2-yl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2SC(Cl)=C(Cl)C=2NC=1C(=O)NC(CO)CC1=CC=CC=C1 FSFFDXIWVZJNNU-UHFFFAOYSA-N 0.000 claims 1
- JUWTUIBOKUUITD-UHFFFAOYSA-N 2,3-dichloro-n-(1-methoxy-2,3-dihydro-1h-inden-2-yl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(OC)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 JUWTUIBOKUUITD-UHFFFAOYSA-N 0.000 claims 1
- JATXYZPMRXZLHH-UHFFFAOYSA-N 2,3-dichloro-n-(2,3-dihydro-1h-inden-2-yl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1C2=CC=CC=C2CC1NC(=O)C1=CC(SC(=C2Cl)Cl)=C2N1 JATXYZPMRXZLHH-UHFFFAOYSA-N 0.000 claims 1
- BZWIVNBVZLWQSN-UHFFFAOYSA-N 2,3-dichloro-n-(2-morpholin-4-yl-2-oxoethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCC(=O)N1CCOCC1 BZWIVNBVZLWQSN-UHFFFAOYSA-N 0.000 claims 1
- MDPWYSDLLSYTBU-UHFFFAOYSA-N 2,3-dichloro-n-(2-oxo-2-thiomorpholin-4-ylethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCC(=O)N1CCSCC1 MDPWYSDLLSYTBU-UHFFFAOYSA-N 0.000 claims 1
- DPEDUCZSPJJIQI-UHFFFAOYSA-N 2,3-dichloro-n-(2-phenoxyethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCCOC1=CC=CC=C1 DPEDUCZSPJJIQI-UHFFFAOYSA-N 0.000 claims 1
- OLVIPIFAMYRLRW-UHFFFAOYSA-N 2,3-dichloro-n-(2-phenylcyclopropyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NC1CC1C1=CC=CC=C1 OLVIPIFAMYRLRW-UHFFFAOYSA-N 0.000 claims 1
- LKAMUERYPRRVDB-UHFFFAOYSA-N 2,3-dichloro-n-(2-phenylethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCCC1=CC=CC=C1 LKAMUERYPRRVDB-UHFFFAOYSA-N 0.000 claims 1
- LKYXKTBZJHVQIR-UHFFFAOYSA-N 2,3-dichloro-n-(6-fluoro-1-hydroxy-2,3-dihydro-1h-inden-2-yl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=C(F)C=C2C(O)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 LKYXKTBZJHVQIR-UHFFFAOYSA-N 0.000 claims 1
- UYGMKKAFEMEBKS-YMTOWFKASA-N 2,3-dichloro-n-[(1r,2r)-1-hydroxy-2,3-dihydro-1h-inden-2-yl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2[C@@H](O)[C@H](NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 UYGMKKAFEMEBKS-YMTOWFKASA-N 0.000 claims 1
- RWMLUGDXHFKJAX-UHFFFAOYSA-N 2,3-dichloro-n-[(4-phenyl-1,2-oxazol-3-yl)methyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCC1=NOC=C1C1=CC=CC=C1 RWMLUGDXHFKJAX-UHFFFAOYSA-N 0.000 claims 1
- LYCQTQJFUNMFHJ-UHFFFAOYSA-N 2,3-dichloro-n-[(4-sulfamoylphenyl)methyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 LYCQTQJFUNMFHJ-UHFFFAOYSA-N 0.000 claims 1
- DXXKGUQVNUYWAW-UHFFFAOYSA-N 2,3-dichloro-n-[1-(methylamino)-2,3-dihydro-1h-inden-2-yl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(NC)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 DXXKGUQVNUYWAW-UHFFFAOYSA-N 0.000 claims 1
- VRACKEYFARMVJV-UHFFFAOYSA-N 2,3-dichloro-n-[2-(3-methoxyphenyl)ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound COC1=CC=CC(CCNC(=O)C=2NC=3C(Cl)=C(Cl)SC=3C=2)=C1 VRACKEYFARMVJV-UHFFFAOYSA-N 0.000 claims 1
- SHGWMYYVPRFEMP-UHFFFAOYSA-N 2,3-dichloro-n-[2-(4-fluorophenyl)ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC(F)=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 SHGWMYYVPRFEMP-UHFFFAOYSA-N 0.000 claims 1
- ZIBLKQVZWYTBLM-UHFFFAOYSA-N 2,3-dichloro-n-[2-(pyridin-2-ylamino)ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCCNC1=CC=CC=N1 ZIBLKQVZWYTBLM-UHFFFAOYSA-N 0.000 claims 1
- BUATVCVONAUNMU-UHFFFAOYSA-N 2,3-dichloro-n-[2-[2-(2-morpholin-4-yl-2-oxoethoxy)phenyl]ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCCC1=CC=CC=C1OCC(=O)N1CCOCC1 BUATVCVONAUNMU-UHFFFAOYSA-N 0.000 claims 1
- VGNDCLZZIZKUOV-UHFFFAOYSA-N 2,3-dichloro-n-[2-[2-(hydroxymethyl)phenyl]ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound OCC1=CC=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 VGNDCLZZIZKUOV-UHFFFAOYSA-N 0.000 claims 1
- NVSMDIROKXNRSW-UHFFFAOYSA-N 2,3-dichloro-n-[2-[2-[2-(4-hydroxypiperidin-1-yl)-2-oxoethoxy]phenyl]ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1CC(O)CCN1C(=O)COC1=CC=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 NVSMDIROKXNRSW-UHFFFAOYSA-N 0.000 claims 1
- VYLACUTZKRPLNY-UHFFFAOYSA-N 2,3-dichloro-n-[2-[2-[2-(dimethylamino)-2-oxoethoxy]phenyl]ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound CN(C)C(=O)COC1=CC=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 VYLACUTZKRPLNY-UHFFFAOYSA-N 0.000 claims 1
- XHJSBLVLKRHMLV-UHFFFAOYSA-N 2,3-dichloro-n-[3-(2h-tetrazol-5-yl)propyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCCCC1=NN=NN1 XHJSBLVLKRHMLV-UHFFFAOYSA-N 0.000 claims 1
- MSJVUARALWRDGD-UHFFFAOYSA-N 2,3-dichloro-n-[[6-(trifluoromethyl)pyridin-3-yl]methyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 MSJVUARALWRDGD-UHFFFAOYSA-N 0.000 claims 1
- ZWDZEGPABRRQRL-UHFFFAOYSA-N 2,3-dichloro-n-imidazo[1,2-a]pyridin-2-yl-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=CC2=NC(NC(=O)C3=CC=4SC(=C(C=4N3)Cl)Cl)=CN21 ZWDZEGPABRRQRL-UHFFFAOYSA-N 0.000 claims 1
- NQDKMZZPUJRMFX-UHFFFAOYSA-N 2,3-dichloro-n-phenacyl-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCC(=O)C1=CC=CC=C1 NQDKMZZPUJRMFX-UHFFFAOYSA-N 0.000 claims 1
- NLJLTGAIWNDJGI-UHFFFAOYSA-N 2-[2-[2-[(2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carbonyl)amino]ethyl]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 NLJLTGAIWNDJGI-UHFFFAOYSA-N 0.000 claims 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- LRHOLHTVXXSIMG-UHFFFAOYSA-N 2-chloro-n-(1-hydroxy-2,3-dihydro-1h-inden-2-yl)-6h-thieno[2,3-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(O)C(NC(=O)C=3NC=4SC(Cl)=CC=4C=3)CC2=C1 LRHOLHTVXXSIMG-UHFFFAOYSA-N 0.000 claims 1
- AZFSIXJWMGOBIS-UHFFFAOYSA-N 2-chloro-n-(2,3-dihydro-1h-inden-2-yl)-6h-thieno[2,3-b]pyrrole-5-carboxamide Chemical compound C1C2=CC=CC=C2CC1NC(=O)C1=CC(C=C(S2)Cl)=C2N1 AZFSIXJWMGOBIS-UHFFFAOYSA-N 0.000 claims 1
- LZRMALFHJSPUEZ-UHFFFAOYSA-N 2-chloro-n-(2-phenoxyethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2SC(Cl)=CC=2NC=1C(=O)NCCOC1=CC=CC=C1 LZRMALFHJSPUEZ-UHFFFAOYSA-N 0.000 claims 1
- GAHMFEQLJBSDKE-UHFFFAOYSA-N 2-chloro-n-(2-phenylcyclopropyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2SC(Cl)=CC=2NC=1C(=O)NC1CC1C1=CC=CC=C1 GAHMFEQLJBSDKE-UHFFFAOYSA-N 0.000 claims 1
- QAHLOPCFUHOCLZ-UHFFFAOYSA-N 2-chloro-n-(2-thiomorpholin-4-ylethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2SC(Cl)=CC=2NC=1C(=O)NCCN1CCSCC1 QAHLOPCFUHOCLZ-UHFFFAOYSA-N 0.000 claims 1
- IKROHIVUCNQKGM-UHFFFAOYSA-N 2-chloro-n-[2-(4-fluorophenyl)ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC(F)=CC=C1CCNC(=O)C(N1)=CC2=C1C=C(Cl)S2 IKROHIVUCNQKGM-UHFFFAOYSA-N 0.000 claims 1
- FFETWUGJXIAOJT-UHFFFAOYSA-N 2-chloro-n-[2-(pyridin-2-ylamino)ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2SC(Cl)=CC=2NC=1C(=O)NCCNC1=CC=CC=N1 FFETWUGJXIAOJT-UHFFFAOYSA-N 0.000 claims 1
- NDIOKJQXEHMGDB-UHFFFAOYSA-N 2-chloro-n-phenacyl-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2SC(Cl)=CC=2NC=1C(=O)NCC(=O)C1=CC=CC=C1 NDIOKJQXEHMGDB-UHFFFAOYSA-N 0.000 claims 1
- SLLCBWHOKBEUCZ-UHFFFAOYSA-N 3-chloro-n-(2-phenoxyethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=CSC=2C=C1C(=O)NCCOC1=CC=CC=C1 SLLCBWHOKBEUCZ-UHFFFAOYSA-N 0.000 claims 1
- APBGPCAPGLJDQR-UHFFFAOYSA-N 3-chloro-n-(2-phenylcyclopropyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=CSC=2C=C1C(=O)NC1CC1C1=CC=CC=C1 APBGPCAPGLJDQR-UHFFFAOYSA-N 0.000 claims 1
- JNNLMLKOWMOQOI-UHFFFAOYSA-N 3-chloro-n-(2-thiomorpholin-4-ylethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=CSC=2C=C1C(=O)NCCN1CCSCC1 JNNLMLKOWMOQOI-UHFFFAOYSA-N 0.000 claims 1
- IMMNOFWGJIRZSV-UHFFFAOYSA-N 3-chloro-n-[2-(4-fluorophenyl)ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC(F)=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=CS2 IMMNOFWGJIRZSV-UHFFFAOYSA-N 0.000 claims 1
- RYZWHPXUBJROJE-UHFFFAOYSA-N 3-chloro-n-phenacyl-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=CSC=2C=C1C(=O)NCC(=O)C1=CC=CC=C1 RYZWHPXUBJROJE-UHFFFAOYSA-N 0.000 claims 1
- DWAIOCIOSRZZHO-UHFFFAOYSA-N 4h-thieno[3,2-b]pyrrole Chemical compound S1C=CC2=C1C=CN2 DWAIOCIOSRZZHO-UHFFFAOYSA-N 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 150000003950 cyclic amides Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- KYMXBGUBBFKNRL-UHFFFAOYSA-N n-(1-acetamido-2,3-dihydro-1h-inden-2-yl)-2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(NC(=O)C)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 KYMXBGUBBFKNRL-UHFFFAOYSA-N 0.000 claims 1
- BMPQTOZEDDKBBV-UHFFFAOYSA-N n-(1-amino-2,3-dihydro-1h-inden-2-yl)-2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(N)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 BMPQTOZEDDKBBV-UHFFFAOYSA-N 0.000 claims 1
- YPMRVUOJBIJKJT-UHFFFAOYSA-N n-[1-[acetyl(methyl)amino]-2,3-dihydro-1h-inden-2-yl]-2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(N(C)C(C)=O)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 YPMRVUOJBIJKJT-UHFFFAOYSA-N 0.000 claims 1
- LGYMIWAYGWVTKU-UHFFFAOYSA-N n-[2-(benzylsulfonylamino)ethyl]-3-chloro-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=CSC=2C=C1C(=O)NCCNS(=O)(=O)CC1=CC=CC=C1 LGYMIWAYGWVTKU-UHFFFAOYSA-N 0.000 claims 1
- KWTXDUHPTGHLNG-UHFFFAOYSA-N n-[2-[2-(2-amino-2-oxoethoxy)phenyl]ethyl]-2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound NC(=O)COC1=CC=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 KWTXDUHPTGHLNG-UHFFFAOYSA-N 0.000 claims 1
- VKWIFFHOFWDMHE-UHFFFAOYSA-N n-benzyl-2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCC1=CC=CC=C1 VKWIFFHOFWDMHE-UHFFFAOYSA-N 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000004526 pyridazin-2-yl group Chemical group N1N(C=CC=C1)* 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 102000051325 Glucagon Human genes 0.000 description 4
- 108060003199 Glucagon Proteins 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 4
- 229960004666 glucagon Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004116 glycogenolysis Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000005505 thiomorpholino group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 2
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- NOLHRFLIXVQPSZ-UHFFFAOYSA-N 1,3-thiazolidin-4-one Chemical compound O=C1CSCN1 NOLHRFLIXVQPSZ-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- HBZHNVUMFPGVHW-UHFFFAOYSA-N 2-chloro-1h-indole Chemical compound C1=CC=C2NC(Cl)=CC2=C1 HBZHNVUMFPGVHW-UHFFFAOYSA-N 0.000 description 1
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- KCIZFYCMKPOFOU-UHFFFAOYSA-N 6h-thieno[2,3-b]pyrrole-5-sulfonamide Chemical class C1=CSC2=C1C=C(S(=O)(=O)N)N2 KCIZFYCMKPOFOU-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010051161 Hyperglucagonaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910021419 crystalline silicon Inorganic materials 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001890 gluconeogenic effect Effects 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000035879 hyperinsulinaemia Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002485 inorganic esters Chemical class 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000003893 regulation of appetite Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0021831.3A GB0021831D0 (en) | 2000-09-06 | 2000-09-06 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200301013B true ZA200301013B (en) | 2004-05-05 |
Family
ID=9898927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200301013A ZA200301013B (en) | 2000-09-06 | 2003-02-05 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20030232875A1 (de) |
| EP (1) | EP1317459B1 (de) |
| JP (1) | JP2004508376A (de) |
| KR (1) | KR100802369B1 (de) |
| CN (2) | CN1264846C (de) |
| AT (1) | ATE263772T1 (de) |
| AU (2) | AU2001282833B2 (de) |
| BG (1) | BG107624A (de) |
| BR (1) | BR0113606A (de) |
| CA (1) | CA2417594A1 (de) |
| CZ (1) | CZ2003616A3 (de) |
| DE (1) | DE60102710T2 (de) |
| DK (1) | DK1317459T3 (de) |
| EE (1) | EE200300083A (de) |
| ES (1) | ES2217183T3 (de) |
| GB (1) | GB0021831D0 (de) |
| HK (1) | HK1055299A1 (de) |
| HU (1) | HUP0400784A3 (de) |
| IL (1) | IL154291A0 (de) |
| IS (1) | IS2110B (de) |
| MX (1) | MXPA03001512A (de) |
| NO (1) | NO20031024L (de) |
| NZ (1) | NZ524011A (de) |
| PL (1) | PL361024A1 (de) |
| PT (1) | PT1317459E (de) |
| RU (1) | RU2003104013A (de) |
| SK (1) | SK2592003A3 (de) |
| TR (1) | TR200401659T4 (de) |
| UA (1) | UA73781C2 (de) |
| WO (1) | WO2002020530A1 (de) |
| ZA (1) | ZA200301013B (de) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5271699A1 (es) | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| DE10215907A1 (de) * | 2002-04-11 | 2003-11-06 | Aventis Pharma Gmbh | Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
| DE10215908B4 (de) * | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel |
| US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| DE10225635C1 (de) * | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
| PT1375477E (pt) * | 2002-06-17 | 2009-11-20 | Saltigo Gmbh | Processo para a preparação de diaminas mono-nsulfoniladas |
| JP4374428B2 (ja) * | 2002-07-11 | 2009-12-02 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 尿素置換されたおよびウレタン置換されたアシル尿素、それらの製造方法および医薬としてのそれらの使用方法 |
| US7186735B2 (en) | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| EP1388535A1 (de) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylierte Arylcycloalkylamine und ihre Anwendung als Arzneimittelwirkstoff |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| CA2503727A1 (en) * | 2002-11-07 | 2004-05-21 | Pfizer Products Inc. | Anti-diabetic agents |
| MXPA05011176A (es) * | 2003-04-17 | 2005-12-14 | Pfizer Prod Inc | Derivados de carboxamida como agentes antidiabeticos. |
| JP2006528702A (ja) * | 2003-05-21 | 2006-12-21 | プロシディオン・リミテッド | グリコーゲンホスホリラーゼのピロロピリジン−２−カルボン酸アミドインヒビター |
| US7405210B2 (en) | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
| WO2004113345A1 (ja) * | 2003-06-20 | 2004-12-29 | Japan Tobacco Inc. | 縮合ピロール化合物及びその医薬用途 |
| GB0318464D0 (en) * | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0318463D0 (en) * | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0319759D0 (en) * | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| GB0319690D0 (en) * | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| WO2005020985A1 (en) * | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity |
| WO2005020986A1 (en) * | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity |
| GB0320422D0 (en) * | 2003-08-30 | 2003-10-01 | Astrazeneca Ab | Chemical compounds |
| CZ2006427A3 (cs) | 2003-12-29 | 2006-11-15 | Sepracor Inc. | Pyrrolové a pyrazolové inhibitory DAAO |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| WO2006055435A1 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| US7226942B2 (en) | 2004-11-15 | 2007-06-05 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7365061B2 (en) | 2004-11-15 | 2008-04-29 | Bristol-Myers Squibb Company | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006053274A2 (en) * | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006059163A1 (en) * | 2004-12-02 | 2006-06-08 | Prosidion Limited | Treatment of diabetes with glycogen phosphorylase inhibitors |
| DE602005008099D1 (de) | 2004-12-02 | 2008-08-21 | Prosidion Ltd | Pyrrolopyridin-2-karbonsäureamid-derivat zur verwendung als inhibitor gegen glykogenphosphorylase |
| EP1841426B1 (de) * | 2005-01-19 | 2011-04-27 | Merck Sharp & Dohme Corp. | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit |
| KR20070107108A (ko) * | 2005-02-05 | 2007-11-06 | 아스트라제네카 아베 | 화학적 화합물 |
| WO2006082400A1 (en) * | 2005-02-05 | 2006-08-10 | Astrazeneca Ab | Indan-amide derivatives with glycogen phosphorylase inhibitory activity |
| ES2566479T3 (es) | 2006-01-06 | 2016-04-13 | Sunovion Pharmaceuticals Inc. | Inhibidores de reabsorción de monoamina con base en tetralona |
| US20070203111A1 (en) | 2006-01-06 | 2007-08-30 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| EP2816024B8 (de) | 2006-03-31 | 2018-04-04 | Sunovion Pharmaceuticals Inc. | Chirale Amine |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US8492405B2 (en) | 2006-10-18 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity |
| US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| JP5420534B2 (ja) | 2007-05-31 | 2014-02-19 | サノビオン ファーマシューティカルズ インク | モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US20100152200A1 (en) * | 2008-11-17 | 2010-06-17 | The Regents Of The University Of Michigan | Alphavirus inhibitors and uses thereof |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CN113388007A (zh) | 2013-06-05 | 2021-09-14 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| EP3186242B1 (de) | 2014-08-29 | 2021-10-06 | Tes Pharma S.r.l. | Inhibitoren von alpha-amino-beta-carboxymuconsäure semialdehyd-decarboxylase |
| AU2016287581B2 (en) * | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
| CR20180413A (es) * | 2016-02-05 | 2018-12-04 | Denali Therapeutics Inc | Inhibidores de la proteína quinasa 1 que interactua con el receptor |
| EP3526199B1 (de) | 2016-10-14 | 2022-04-13 | Tes Pharma S.r.l. | Inhibitoren der alpha-amino-beta-carboxymuconsäure-semialdehyddecarboxylase |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| CN113302189A (zh) | 2018-11-20 | 2021-08-24 | Tes制药有限责任公司 | α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂 |
| JPWO2021106988A1 (de) * | 2019-11-27 | 2021-06-03 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3706810A (en) * | 1970-09-15 | 1972-12-19 | American Cyanamid Co | N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides |
| US4692522A (en) * | 1985-04-01 | 1987-09-08 | Merck & Co., Inc. | Benzofused lactams useful as cholecystokinin antagonists |
| US4599198A (en) * | 1985-08-02 | 1986-07-08 | Pfizer Inc. | Intermediates in polypeptide synthesis |
| US4668769A (en) * | 1985-08-02 | 1987-05-26 | Hoover Dennis J | Oxa- and azahomocyclostatine polypeptides |
| US4720503A (en) * | 1985-08-02 | 1988-01-19 | Merck & Co., Inc. | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
| FR2601368B1 (fr) * | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
| DE3629545A1 (de) * | 1986-08-30 | 1988-03-10 | Bayer Ag | Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| US4751231A (en) * | 1987-09-16 | 1988-06-14 | Merck & Co., Inc. | Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents |
| ES2081747B1 (es) * | 1993-09-07 | 1997-01-16 | Esteve Labor Dr | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. |
| US5863903A (en) * | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| FR2723739B1 (fr) * | 1994-08-19 | 1997-02-14 | Sanofi Sa | Derives de glycinamide, procedes pour leur preparation et medicaments les contenant. |
| MX9709875A (es) * | 1995-06-06 | 1998-03-31 | Pfizer | N-(indol-2-carbonil)-glicinamidas substituidas y derivados como inhibidores de glicogeno fosforilasa, composiciones que las contienen y uso de las mismas. |
| US5952322A (en) * | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| WO1999046268A1 (en) * | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| ES2211454T3 (es) * | 1999-09-30 | 2004-07-16 | Pfizer Products Inc. | Pirrolilamidas como inhibidores de la colageno fosforilasa. |
| CO5271699A1 (es) * | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
| US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
-
2000
- 2000-09-06 GB GBGB0021831.3A patent/GB0021831D0/en not_active Ceased
-
2001
- 2001-08-31 DE DE60102710T patent/DE60102710T2/de not_active Expired - Fee Related
- 2001-08-31 AT AT01961577T patent/ATE263772T1/de not_active IP Right Cessation
- 2001-08-31 WO PCT/SE2001/001880 patent/WO2002020530A1/en active IP Right Grant
- 2001-08-31 PL PL01361024A patent/PL361024A1/xx unknown
- 2001-08-31 TR TR2004/01659T patent/TR200401659T4/xx unknown
- 2001-08-31 MX MXPA03001512A patent/MXPA03001512A/es active IP Right Grant
- 2001-08-31 IL IL15429101A patent/IL154291A0/xx unknown
- 2001-08-31 CN CNB018183220A patent/CN1264846C/zh not_active Expired - Fee Related
- 2001-08-31 UA UA2003021026A patent/UA73781C2/uk unknown
- 2001-08-31 US US10/344,506 patent/US20030232875A1/en not_active Abandoned
- 2001-08-31 EE EEP200300083A patent/EE200300083A/xx unknown
- 2001-08-31 CA CA002417594A patent/CA2417594A1/en not_active Abandoned
- 2001-08-31 RU RU2003104013/04A patent/RU2003104013A/ru not_active Application Discontinuation
- 2001-08-31 JP JP2002525151A patent/JP2004508376A/ja not_active Withdrawn
- 2001-08-31 HU HU0400784A patent/HUP0400784A3/hu unknown
- 2001-08-31 ES ES01961577T patent/ES2217183T3/es not_active Expired - Lifetime
- 2001-08-31 BR BR0113606-2A patent/BR0113606A/pt not_active IP Right Cessation
- 2001-08-31 KR KR1020037003265A patent/KR100802369B1/ko not_active IP Right Cessation
- 2001-08-31 CZ CZ2003616A patent/CZ2003616A3/cs unknown
- 2001-08-31 EP EP01961577A patent/EP1317459B1/de not_active Expired - Lifetime
- 2001-08-31 DK DK01961577T patent/DK1317459T3/da active
- 2001-08-31 AU AU2001282833A patent/AU2001282833B2/en not_active Ceased
- 2001-08-31 PT PT01961577T patent/PT1317459E/pt unknown
- 2001-08-31 SK SK259-2003A patent/SK2592003A3/sk unknown
- 2001-08-31 AU AU8283301A patent/AU8283301A/xx active Pending
- 2001-08-31 NZ NZ524011A patent/NZ524011A/en unknown
- 2001-08-31 CN CNA2006100818966A patent/CN1896078A/zh active Pending
-
2003
- 2003-02-05 ZA ZA200301013A patent/ZA200301013B/en unknown
- 2003-02-24 IS IS6727A patent/IS2110B/is unknown
- 2003-03-05 NO NO20031024A patent/NO20031024L/no not_active Application Discontinuation
- 2003-03-10 BG BG107624A patent/BG107624A/bg unknown
- 2003-10-16 HK HK03107519A patent/HK1055299A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200301013B (en) | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors. | |
| ZA200200028B (en) | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine devatives. | |
| CN102869666B (zh) | 用于疾病治疗的组胺受体的杂环抑制剂 | |
| AU767452B2 (en) | Method of treating nitrate-induced tolerance | |
| JP2004508376A5 (de) | ||
| CN102186479A (zh) | 用于治疗疾病的组胺受体的氨基嘧啶抑制剂 | |
| AU2006301650A1 (en) | Microangiopathy treatment and prevention | |
| ZA200606243B (en) | Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation | |
| CA2584303A1 (en) | Novel heterocycles | |
| CN1307183C (zh) | 具有糖原磷酸化酶抑制活性的杂环酰胺衍生物 | |
| US6495554B2 (en) | Thienopyrimidines | |
| ZA200406679B (en) | Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase. | |
| DE102006051625A1 (de) | Kombinationstherapie substituierter Oxazolidinone | |
| RU2006136880A (ru) | Фармацевтическая композиция, содержащая производные бензодиазепина и ингибитор белка слияния rsv | |
| CN106661002A (zh) | 用于治疗炎性、代谢性、肿瘤性和自身免疫性疾病的任选稠合的、经杂环基取代的嘧啶衍生物 | |
| CN100374420C (zh) | 具有糖原磷酸化酶抑制活性的吲哚酰胺衍生物 | |
| CA2756689A1 (en) | Treatment of osteoarthritis pain | |
| CA2577664A1 (en) | Novel heterocycles | |
| WO2007079914A2 (en) | Combination of triazine derivatives and insulin secretion stimulators | |
| AU781607B2 (en) | Isoxazole derivatives to be used as phosphodiesterase VII inhibitors | |
| CN106103439A (zh) | 2,7‑二氮杂螺[3.5]壬烷化合物 | |
| AU2007315932A1 (en) | A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect | |
| MXPA03009125A (es) | Derivados de aril (o heteroaril), azolilcarbinoles para el tratamiento de enfermedades respiratorias. | |
| AU2001237379B2 (en) | Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction | |
| NZ207917A (en) | Pharmaceutical compositions containing co-dergocrine and a calcium antagonist |